EUCTR2013-002860-19-NL进行中(未招募)不适用
The risk of cardiovascular disease in Ankylosing Spondylitis; A Single Center Cross-Sectional Study Evaluating The Association Between Inflammation In Ankylosing Spondylitis And Vascular Inflammation - AS risk
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- AMC
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects with AS
- •?Age: =18 years
- •?Diagnosis of AS (following the 1984 Modified New York Criteria for ankylosing Spondylitis (16)) + disease duration since start of first symptoms for a period of more than 3 years.
- •?Subject agrees to the restrictions as described in paragraph 4.4.2. In brief: subjects are not permitted any alcohol or caffeine-containing food or drinks from 12 hrs prior to study visits until discharge. In addition, no strenuous exercise is permitted for 24 hrs before the study visits
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects may not enter this study if they meet the following criteria
- •?BMI > 30.
- •?History of diabetes mellitus/insulin use
- •?Hypertension/use of blood pressure lowering medication
- •?Use of statins prior to inclusion, or contra-indications for statin use.
- •?History of cardiovascular events
- •?Proven or suspected bacterial infections. Recent (<1 month prior to screening) or ongoing
- •?Serious infection requiring IV antibiotic therapy.
- •?Recent or current treatment with medications that may have a significant effect on plaque Inflammation as measured by plaque TBR, including but not limited to: Biological based medicines (anti-TNF (ex. Infliximab), anti-IL-6 therapy (ex. Tocilizumab) or anti-IL-1 (ex. anakinra)) within 8 weeks before the baseline visit and during the study.
- •?Any clinically significant medical condition that could interfere with the conduct of the study.
- •?Standard contra-indications to MRI, 18FDG PET, and CT, including pregnancy and lactating women.
- •?Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
- •?Subject has planned cardiac surgery, PCI or carotid stenting, or major non-cardiac surgery during the course of the study period or for 14 days after the last treatment.
研究者
相似试验
已完成
不适用
The risk of cardiovascular disease in Ankylosing Spondylitis: A Single Center Cross-Sectional Study Evaluating The Association Between Inflammation In Ankylosing Spondylitis And Vascular InflammatioBechterew100110821000381610003216NL-OMON37301Academisch Medisch Centrum25
招募中
不适用
Cardiac disease in Ankylosing SpondylitisAnkylosing spondylitis, osteoartritisNL-OMON25008Reade192
已完成
不适用
Cardiac disease in Ankylosing SpondylitisAnkylosing SpondylitisNL-OMON41462Jan van Breemen Instituut400
招募中
不适用
Keio Cardiovascular Study on Pathogenesis of Anticancer Drugs Contributing to Cardiovascular EventsCancerJPRN-UMIN000033773Keio University5,000
Unknown
不适用
Cardiovascular disease in ANCA-associated vasculitisANCA-associated vasculitisNL-OMON24348orthwest Academy210
